The Karnataka High Court has upheld a three-year blacklisting of a pharmaceutical company after its supplied drugs were found to be 'Not of Standard Quality' in laboratory tests. The ruling clarifies that procurement agencies like KSMSCL are not responsible for furnishing drug analysis reports—that duty rests solely with the Drug Inspectorate under the Drugs and Cosmetics Act, 1940. This decision has implications for medical aesthetics suppliers and distributors operating in India, as it reinforces the legal boundaries between procurement entities and statutory regulators.
Court ruling and key distinction
The Court, presided over by Justice Suraj Govindaraj, drew a clear line between the roles of KSMSCL as a procurement agency and the Drug Inspectorate as the statutory authority. It held that any obligation to provide the Government Analyst's report and sample portions under the Drugs and Cosmetics Act lies with the Drug Inspectorate, not KSMSCL. The petitioner's claim of non-compliance with Rule 26A of the Karnataka Transparency in Public Procurements Rules was rejected, as the blacklisting action was taken under a contractual clause in the tender conditions, not under the statutory rule.
Natural justice and contractual blacklisting
The Court emphasized that even when blacklisting is contractual, principles of natural justice apply if the action results in serious civil consequences. However, it found that the petitioner had been given adequate opportunity to respond to allegations. The Court noted that the petitioner had not initiated any proceedings under the Drugs and Cosmetics Act to challenge the Government Analyst's report, describing this as a 'defensive tactic' rather than a genuine grievance. The ruling confirms that procurement entities can act on valid statutory reports without being required to follow Rule 26A procedures.
What buyers and distributors should watch
For overseas importers, distributors, and clinic buyers sourcing from or through Indian procurement agencies, this ruling underscores the importance of understanding the regulatory framework. The Drug Inspectorate remains the sole authority for drug quality analysis and report furnishing. Buyers should ensure that their contracts with Indian suppliers include clear clauses for quality dispute resolution and that they maintain direct communication with statutory authorities for any quality-related concerns. The decision also highlights that contractual blacklisting can proceed independently of statutory procedures, provided natural justice is observed.
Sourcing context
KSMSCL is a key procurement entity for medical supplies in Karnataka, India. This ruling clarifies that procurement agencies are not required to follow the same procedures as statutory regulators when blacklisting suppliers for quality failures. For medical aesthetics companies, this means that quality compliance with the Drugs and Cosmetics Act is paramount, and any disputes over analysis reports must be addressed directly with the Drug Inspectorate, not the procurement agency. The decision reinforces the need for robust quality assurance systems and proactive legal remedies when facing quality allegations.
Source: Read the original report | Published: June 12, 2026